Oncimmune Holdings PLC Grant of Options and PDMR Dealing (2466S)

TIDMONC

RNS Number : 2466S

Oncimmune Holdings PLC

13 July 2022

13 July 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Grant of Options and PDMR Dealing

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that options to subscribe for ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") have been granted to Alistair Macdonald following his appointment as the Company's Non-executive Chair on 8 July 2022.

Alistair Macdonald has been granted 127,389 options at an exercise price of GBP0.785 per Ordinary Share and 492,252 options (the "Scheme Options") at an exercise price of GBP0.01 per Ordinary Share pursuant to the incentivisation scheme established for members of senior management in September 2020 (the "Scheme"). The Scheme Options will vest based on the performance of the Company's share price over the course of the three years from the establishment of the Scheme, between GBP2.00 and GBP3.50 ("Target Share Price") (as set out below), which must be achieved for 20 consecutive business days or on certain trigger event. This vesting mechanism is directly aligned with the delivery of shareholder value. Once vested, Options (or resulting shares) must be held for a further two years, subject to certain exceptions and acceleration events. The Target Share Prices and associated vesting levels for Alistair Macdonald's Scheme Options are as follows:

 
               Target Share Price 
 GBP2.00   GBP2.50   GBP2.75   GBP3.00   GBP3.50 
          --------  --------  --------  -------- 
           Percentage of Award Vesting 
   25%       50%      62.5%      75%      100% 
          --------  --------  --------  -------- 
         Total Number of Options Vesting 
 123,063   246,126   307,658   369,189   492,252 
          --------  --------  --------  -------- 
 

The Scheme Options granted to Alistair Macdonald replace the unvested options granted to former Chair Meinhard Schmidt in September 2020, which have now lapsed following Meinhard's retirement from the Board.

This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation and serves as notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them.

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                              Alistair Macdonald 
      --------------------------------  -------------------------------------- 
       Reason for the notification 
  2 
      ------------------------------------------------------------------------ 
 a)    Position/status                   Non-executive Chair 
      --------------------------------  -------------------------------------- 
 b)    Initial notification              Initial notification 
        /Amendment 
      --------------------------------  -------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------ 
 a)    Name                              Oncimmune Holdings plc 
      --------------------------------  -------------------------------------- 
 b)    LEI                               213800HCYIWT6YPI1I02 
      --------------------------------  -------------------------------------- 
       Details of the transaction(s): section to be repeated for 
  4     (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      ------------------------------------------------------------------------ 
 a)    Description                       Ordinary Shares of GBP0.01 each 
        of the financial 
        instrument, 
        type of instrument 
 
       Identification                    ISIN: GB00BYQ94H38 
        code 
 
 b)    Nature of the                     1) Grant of options 
        transaction                       2) Grant of Scheme Options 
      --------------------------------  -------------------------------------- 
 c)    Price(s) and 
        volume(s) 
                                         -------------------  -------------- 
                                          Price(s)             Volume(s) 
                                         -------------------  -------------- 
    1) GBP0.785                                                127,389 
   ---------------------------------------------------------  -------------- 
    2) GBP0.01                                                 492,252 
   ---------------------------------------------------------  -------------- 
 
 d)    Aggregated                        N/A - single transactions 
        information 
 
  - Aggregated 
   volume 
 
  - Price 
 
 e)    Date of the                       12 July 2022 
        transaction 
      --------------------------------  -------------------------------------- 
 f)    Place of the                      Outside a trading venue 
        transaction 
      --------------------------------  -------------------------------------- 
 

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

[phone]

Media enquiries:

John Goold

[e-mail]

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to GBP3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit www.oncimmune.com

What is SeroTag(TM) ?

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers can help stratify patients in multiple cancer indications and with different autoimmune diseases.

This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally invasive liquid biopsies. SeroTag analyses autoantibodies-some of the most stable analytes-and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.

The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune's NavigAID(TM) disease-specific stratification panels. These precision medicine tools which are enabling patient and disease stratification and support therapeutic development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBKBBBFBKDDOD

(END) Dow Jones Newswires

July 13, 2022 02:00 ET (06:00 GMT)